Search

everythinglearnresearchcommunity

for

Search:↓

The LRRK2-G2019S mutation in Parkinson's disease has a lifetime penetrance of 25-35%, and finasteride may help reduce symptoms in adult male Tourette syndrome patients.

Finasteride reduces Tourette syndrome symptoms, but results may be limited due to potential biases.

Finasteride may help reduce symptoms in male Tourette syndrome patients.

The document describes a woman with familial Parkinson's disease due to a genetic mutation, showing severe symptoms and poor response to treatment, and suggests finasteride may help reduce symptoms in Tourette syndrome.

The document concludes that managing side effects of MS therapies is crucial for treatment success and patient adherence.

Finasteride significantly reduced tics and obsessive-compulsive symptoms in patients with Tourette syndrome.

THAP1 gene changes do not affect DYT1 dystonia; finasteride may help reduce tics and OCD in Tourette syndrome.

A man developed a rare blood vessel connection on his scalp after hair transplants, which was successfully treated with surgery.

A specific gene mutation is linked to a hereditary form of dystonia that responds well to certain medications.

Finasteride significantly reduced tics and obsessive-compulsive symptoms in Tourette syndrome patients.

Finasteride may help reduce tic severity in male Tourette syndrome patients.

SLE patients need careful diagnosis to distinguish infections from disease flares for proper treatment.

A boy with GAPO syndrome had hair loss similar to male pattern baldness without hormone issues, possibly due to skin or blood vessel problems.

Early diagnosis and treatment of achalasia and hyperthyroidism improve patient outcomes.

A patient produced cortisol after adrenalectomy, possibly due to residual tissue or other body parts making steroids.

Alopecia areata is relatively common in children, has a variable course, and shows different responses to treatment; thyroid testing is recommended for those affected.

Mutations in the SRD5A3 gene cause a new type of glycosylation disorder by blocking the production of a molecule necessary for protein glycosylation.

The document explains how the male reproductive system works, its role in making testosterone, and how conditions like obesity can disrupt it, leading to low testosterone and fertility issues.

Woodhouse-Sakati syndrome often causes sexual development issues, hair loss, learning disabilities, deafness, muscle contractions, limb pain, and diabetes.

The document reports three sisters with Woodhouse-Sakati syndrome showing typical symptoms and unusual gynecological anomalies.

Two patients developed complete hair loss after Alemtuzumab treatment for MS, with no regrowth after two years.

The document reports findings on genetic research, including ethical concerns about genome editing, improved diagnosis of mitochondrial mutations, solving inherited eye diseases, confirming gene roles in epilepsy, linking a gene to aneurysms, and identifying genes associated with age-related macular degeneration.

The meeting discussed medical findings, including benefits of certain treatments for cancer and heart conditions, and highlighted issues like poor adherence to preventive measures and skill gaps among interns.

The Rotterdam Study investigates diseases in older adults and has produced many research findings.

The Rotterdam Study aims to understand disease causes in the elderly and has found new risk factors and genetic influences on various conditions.

The Rotterdam Study updated its design and objectives in 2012, providing insights into various diseases in the elderly, including skin cancer, bone health, liver disease, neurological and psychiatric conditions, and respiratory issues.

The Rotterdam Study aims to understand various diseases in older adults.

The guidelines suggest a detailed approach to diagnosing and treating lupus, with a focus on regular check-ups, personalized medicine, and a range of drug options for different cases.

Some people experience severe, long-lasting side effects from fluoroquinolone antibiotics, leading to the recommendation of limited use and increased awareness of these risks.

Ruxolitinib significantly improves multiple autoimmune conditions in APS-1 patients.